Chardan Capital Has Strong Forecast for COYA FY2025 Earnings

Coya Therapeutics, Inc. (NASDAQ:COYA) – Analysts at Chardan Capital raised their FY2025 earnings per share (EPS) estimates for Coya Therapeutics in a research note issued to investors on Monday, March 24th. Chardan Capital analyst K. Nakae now forecasts that the company will post earnings per share of ($1.03) for the year, up from their prior estimate of ($1.26). Chardan Capital currently has a “Buy” rating and a $14.00 target price on the stock. The consensus estimate for Coya Therapeutics’ current full-year earnings is ($1.15) per share.

Coya Therapeutics (NASDAQ:COYA) last released its earnings results on Tuesday, March 18th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.14. The firm had revenue of $0.20 million for the quarter, compared to the consensus estimate of $0.10 million.

Separately, D. Boral Capital reaffirmed a “buy” rating and set a $18.00 price target on shares of Coya Therapeutics in a research report on Tuesday, March 18th.

Coya Therapeutics Trading Down 0.6 %

Coya Therapeutics stock opened at $6.51 on Thursday. The firm has a market capitalization of $108.88 million, a P/E ratio of -10.02 and a beta of 0.31. The business has a 50-day moving average of $6.38 and a 200-day moving average of $6.50. Coya Therapeutics has a 1 year low of $4.75 and a 1 year high of $10.24.

Hedge Funds Weigh In On Coya Therapeutics

A number of large investors have recently modified their holdings of the business. Northern Trust Corp increased its position in shares of Coya Therapeutics by 12.2% in the fourth quarter. Northern Trust Corp now owns 28,549 shares of the company’s stock valued at $164,000 after acquiring an additional 3,099 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Coya Therapeutics by 3.3% during the 3rd quarter. Geode Capital Management LLC now owns 142,309 shares of the company’s stock worth $918,000 after purchasing an additional 4,485 shares during the last quarter. Tower Research Capital LLC TRC raised its stake in shares of Coya Therapeutics by 1,005.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,252 shares of the company’s stock worth $30,000 after purchasing an additional 4,777 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Coya Therapeutics in the 4th quarter valued at approximately $59,000. Finally, Jane Street Group LLC bought a new position in shares of Coya Therapeutics in the fourth quarter valued at $74,000. 39.75% of the stock is currently owned by institutional investors and hedge funds.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.